Short-term cost-effectiveness of one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage expander-implant reconstruction from a multicentre randomized clinical trial
Authors:
Open Access
- 5 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (5) , 586-595
Abstract
Background Implant‐based breast reconstruction (IBBR) is the most commonly performed reconstructive procedure and its economic impact is significant. This study aimed to analyse whether a direct one‐stage IBBR with use of an acellular dermal matrix (ADM) is more cost‐effective than two‐stage (expander‐implant) breast reconstruction. Methods The BRIOS (Breast Reconstruction In One Stage) study was an open‐label multicentre RCT in which women scheduled for skin‐sparing mastectomy and immediate IBBR were randomized between one‐stage IBBR with ADM or two‐stage IBBR. Duration of surgery and hospital stay, and visits for the primary surgery, unplanned and cosmetic procedures were recorded. Costs were estimated at an institutional level. Health status was assessed by means of the EuroQol Five Dimensions 5L questionnaire. Results Fifty‐nine patients (91 breasts) underwent one‐stage IBBR with ADM and 62 patients (92 breasts) two‐stage IBBR. The mean(s.d.) duration of surgery in the one‐stage group was significantly longer than that for two‐stage IBBR for unilateral (2·52(0·55) versus 2·02(0·35) h; P < 0·001) and bilateral (4·03(1·00) versus 3·25(0·58) h; P = 0·017) reconstructions. Costs were higher for one‐stage compared with two‐stage IBBR for both unilateral (€12 448 (95 per cent c.i. 10 722 to 14 387) versus €9871 (9373 to 10 445) respectively; P = 0·025) and bilateral (€16 939 (14 887 to 19 360) versus €13 383 (12 414 to 14 669); P = 0·002) reconstructions. This was partly related to the use of relatively expensive ADM. There was no difference in postoperative health status between the groups. Conclusion One‐stage IBBR with ADM was associated with higher costs, but similar health status, compared with conventional two‐stage IBBR. Registration number: NTR5446 ( http://www.trialregister.nl).Keywords
Funding Information
- Funds Nuts-Ohra
- Life Cell Corporation
- Pink Ribbon Foundation
- Fonds NutsOhra
- Pink Ribbons Project
This publication has 22 references indexed in Scilit:
- Short-Term Complications Associated With Acellular Dermal Matrix-Assisted Direct-to-Implant Breast ReconstructionAnnals of Plastic Surgery, 2017
- Systematic review and critical appraisal of the impact of acellular dermal matrix use on the outcomes of implant-based breast reconstructionBritish Journal of Surgery, 2015
- Immediate breast reconstruction with acellular dermal matrix: Factors affecting outcomeJournal of Plastic, Reconstructive & Aesthetic Surgery, 2014
- The cost effectiveness of acellular dermal matrix in expander–implant immediate breast reconstructionJournal of Plastic, Reconstructive & Aesthetic Surgery, 2014
- A Comparison of Acellular Dermal Matrix to Autologous Dermal Flaps in Single-Stage, Implant-Based Immediate Breast ReconstructionPlastic and Reconstructive Surgery, 2013
- Cost minimisation analysis of using acellular dermal matrix (Strattice™) for breast reconstruction compared with standard techniquesEuropean Journal of Surgical Oncology, 2013
- Cost Analysis of Implant-Based Breast Reconstruction With Acellular Dermal MatrixAnnals of Plastic Surgery, 2012
- Breast cancer survival in the US and Europe: A CONCORD high‐resolution studyInternational Journal of Cancer, 2012
- Retrospective Review of 331 Consecutive Immediate Single-Stage Implant Reconstructions with Acellular Dermal MatrixPlastic and Reconstructive Surgery, 2011
- The Use of AlloDerm in Postmastectomy Alloplastic Breast Reconstruction: Part II. A Cost AnalysisPlastic and Reconstructive Surgery, 2011